Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Actinogen Medical ( (AU:ACW) ) has issued an update.
Actinogen Medical Limited has announced the quotation of 101,001 fully paid ordinary securities on the Australian Securities Exchange (ASX) as of December 12, 2025. This move is part of the company’s strategic efforts to enhance its market presence and provide more liquidity for its shareholders, potentially impacting its operations and positioning within the biotechnology sector.
The most recent analyst rating on (AU:ACW) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.
More about Actinogen Medical
Actinogen Medical Limited operates in the biotechnology industry, focusing on the development of innovative treatments for cognitive impairment and related conditions. The company’s primary product offerings are centered around addressing neurological disorders, with a significant emphasis on enhancing cognitive health.
Average Trading Volume: 4,304,316
Technical Sentiment Signal: Buy
Current Market Cap: A$175M
See more insights into ACW stock on TipRanks’ Stock Analysis page.